Skip to main content
Top
Published in: Medical Oncology 5/2012

01-12-2012 | Original Paper

Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion

Authors: Jian-Jun Ma, Ling-Min Kong, Cheng-Gong Liao, Xue Jiang, Yong Wang, Ting-Yi Bao

Published in: Medical Oncology | Issue 5/2012

Login to get access

Abstract

Members of the NDRG (N-Myc downstream-regulated) gene family have been shown to play a variety of roles in human malignancies. Recently, it was shown decreased expression in clear cell renal cell carcinoma (CCRCC) and inhibited cell proliferation, but the role of the NDRG2 in CCRCC invasion has not been described. We examined the expression of NDRG2 protein in CCRCC samples and the association between NDRG2 expression and CCRCC patients survival. Real-time RT-PCR and immunohistochemical analysis were used to measure NDRG2 expression in 60 paired CCRCC and adjacent normal tissues. Changes in cell invasion were detected by up- or down-regulating NDRG2 by adenovirus or siRNA. We found that NDRG2 expression is significantly down-regulated in CCRCC at mRNA and protein levels in a manner negatively associated with aggressive tumor behaviors, such as TNM stage (P = 0.003), Fuhrman’s grade (P = 0.024), tumor invasion (P = 0.001) and tumor recurrence (P = 0.004), as well as shorter patient survival rates (P = 0.0041). Furthermore, NDRG2 could suppress CCRCC cell invasion through regulating MMP-9 expression and activity. So, these results suggest that NDRG2 can inhibit extracellular matrix-based tumor cell invasion and thereby play important roles in suppressing tumor metastasis in CCRCC. NDRG2 expression may also be a significant prognostic indicator for CCRCC.
Literature
2.
go back to reference Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000.PubMedCrossRef Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000.PubMedCrossRef
3.
go back to reference Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol. 2009;41(4):753–6.PubMedCrossRef Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol. 2009;41(4):753–6.PubMedCrossRef
4.
go back to reference Sjolund J, Bostrom AK, et al. The Notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS ONE. 2011;6(8):e23057.PubMedCrossRef Sjolund J, Bostrom AK, et al. The Notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS ONE. 2011;6(8):e23057.PubMedCrossRef
5.
go back to reference Qu X, Zhai Y, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.PubMedCrossRef Qu X, Zhai Y, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.PubMedCrossRef
6.
go back to reference Deng Y, Yao L, et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106(3):342–7.PubMedCrossRef Deng Y, Yao L, et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106(3):342–7.PubMedCrossRef
7.
go back to reference Hummerich L, Muller R, et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25(1):111–21.PubMed Hummerich L, Muller R, et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25(1):111–21.PubMed
8.
go back to reference Lusis EA, Watson MA, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65(16):7121–6.PubMedCrossRef Lusis EA, Watson MA, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65(16):7121–6.PubMedCrossRef
9.
go back to reference Ma J, Jin H, et al. Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull. 2008;31(7):1316–20.PubMedCrossRef Ma J, Jin H, et al. Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull. 2008;31(7):1316–20.PubMedCrossRef
10.
go back to reference Ma JJ, Liao CG, et al. NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498. J Exp Clin Cancer Res. 2010;29:103.PubMedCrossRef Ma JJ, Liao CG, et al. NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498. J Exp Clin Cancer Res. 2010;29:103.PubMedCrossRef
11.
go back to reference Kim A, Kim MJ, et al. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis. 2009;30(6):927–36.PubMedCrossRef Kim A, Kim MJ, et al. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis. 2009;30(6):927–36.PubMedCrossRef
12.
go back to reference Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.PubMedCrossRef Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.PubMedCrossRef
13.
go back to reference Shon SK, Kim A, et al. Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun. 2009;385(2):198–203.PubMedCrossRef Shon SK, Kim A, et al. Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun. 2009;385(2):198–203.PubMedCrossRef
14.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedCrossRef
15.
go back to reference Caceres W, Cruz-Chacon A. Renal cell carcinoma: molecularly targeted therapy. P R Health Sci J. 2011;30(2):73–7.PubMed Caceres W, Cruz-Chacon A. Renal cell carcinoma: molecularly targeted therapy. P R Health Sci J. 2011;30(2):73–7.PubMed
16.
go back to reference Draube A, Klein-Gonzalez N, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011;6(4):e18801.PubMedCrossRef Draube A, Klein-Gonzalez N, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011;6(4):e18801.PubMedCrossRef
17.
go back to reference Liu N, Wang L, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):164–9.PubMedCrossRef Liu N, Wang L, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):164–9.PubMedCrossRef
18.
go back to reference Choi SC, Yoon SR, et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39(6):705–14.PubMed Choi SC, Yoon SR, et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39(6):705–14.PubMed
19.
go back to reference Zheng J, Li Y, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer. 2011;251:1–9. Zheng J, Li Y, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer. 2011;251:1–9.
20.
go back to reference Li W, Chu D, et al. Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci. 2011;18(11):1534–7.PubMedCrossRef Li W, Chu D, et al. Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci. 2011;18(11):1534–7.PubMedCrossRef
21.
go back to reference Jiang ZQ, Zhu FC, Qu JY, Zheng X, You CL. Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix. Ai Zheng. 2003;22(2):178–84.PubMed Jiang ZQ, Zhu FC, Qu JY, Zheng X, You CL. Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix. Ai Zheng. 2003;22(2):178–84.PubMed
22.
go back to reference Cosic SJ, Kovac Z. Clinical and etiopathogenetic role of plasminogen and metaloproteinase systems in the tumor growth. Pericellular proteolysis of extracellular matrix and tumor growth. Lijec Vjesn. 2011;133(1–2):56–63.PubMed Cosic SJ, Kovac Z. Clinical and etiopathogenetic role of plasminogen and metaloproteinase systems in the tumor growth. Pericellular proteolysis of extracellular matrix and tumor growth. Lijec Vjesn. 2011;133(1–2):56–63.PubMed
23.
go back to reference Szczepanska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M. Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(4):257–60.PubMed Szczepanska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M. Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(4):257–60.PubMed
Metadata
Title
Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion
Authors
Jian-Jun Ma
Ling-Min Kong
Cheng-Gong Liao
Xue Jiang
Yong Wang
Ting-Yi Bao
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0265-1

Other articles of this Issue 5/2012

Medical Oncology 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine